Skip to content
Multaq(dronedarone)
Multaq (dronedarone) is a small molecule pharmaceutical. Dronedarone was first approved as Multaq on 2009-07-01. It is used to treat atrial fibrillation and cardiac arrhythmias in the USA. It has been approved in Europe to treat atrial fibrillation. It is known to target potassium voltage-gated channel subfamily A member 5.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
cardiovascular diseasesD002318
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
Multaq
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Dronedarone hydrochloride
Tradename
Company
Number
Date
Products
MULTAQSanofiN-022425 RX2009-07-01
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
multaqNew Drug Application2021-01-04
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
atrial fibrillationEFO_0000275D001281I48.0
cardiac arrhythmiasEFO_0004269D001145I49.9
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent
Expires
Flag
FDA Information
Dronedarone Hydrochloride, Multaq, Sanofi Aventis Us
86022152031-06-30U-1473
84101672029-04-16U-1387, U-1388
91079002029-04-16U-1726, U-1728
ATC Codes
C: Cardiovascular system drugs
— C01: Cardiac therapy drugs
— C01B: Antiarrhythmics, class i and iii
— C01BD: Antiarrhythmics, class iii
— C01BD07: Dronedarone
HCPCS
No data
Clinical
Clinical Trials
28 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Atrial fibrillationD001281EFO_0000275I48.0—3810525
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Atrial flutterD001282EFO_0003911——3——3
Heart failureD006333EFO_0003144I50——1——1
Indications Phases 2
No data
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients—1————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Cardiac arrhythmiasD001145EFO_0004269I49.9————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameDRONEDARONE
INNdronedarone
Description
Dronedarone is a member of the class of 1-benzofurans used for the treatment of cardiac arrhythmias. It has a role as an anti-arrhythmia drug, an environmental contaminant and a xenobiotic. It is a member of 1-benzofurans, a tertiary amino compound, a sulfonamide, an aromatic ketone and an aromatic ether.
Classification
Small molecule
Drug classantiarrhythmics
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CCCCc1oc2ccc(NS(C)(=O)=O)cc2c1C(=O)c1ccc(OCCCN(CCCC)CCCC)cc1
Identifiers
PDB—
CAS-ID141626-36-0
RxCUI233698
ChEMBL IDCHEMBL184412
ChEBI ID50659
PubChem CID208898
DrugBankDB04855
UNII IDJQZ1L091Y2 (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
KCNA5
KCNA5
Organism
Homo sapiens
Gene name
KCNA5
Gene synonyms
NCBI Gene ID
3741
Protein name
potassium voltage-gated channel subfamily A member 5
Protein synonyms
cardiac potassium channel, HPCN1, insulinoma and islet potassium channel, potassium channel 1, potassium channel, voltage gated shaker related subfamily A, member 5, potassium voltage-gated channel, shaker-related subfamily, member 5, Voltage-gated potassium channel HK2, voltage-gated potassium channel protein Kv1.5, Voltage-gated potassium channel subunit Kv1.5
Uniprot ID
Q9UDA4
Mouse ortholog
Kcna5 (16493)
potassium voltage-gated channel subfamily A member 5 (Q9Z1R6)
Variants
Clinical Variant
No data
Financial
Multaq - Sanofi
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 2,117 documents
View more details
Safety
Black-box Warning
Black-box warning for: Multaq
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
16,260 adverse events reported
View more details